Comparing Propofol and Dexmedetomidine for Reducing Postoperative Nausea and Vomiting
The Effect of Propofol Versus Dexmedetomidine on the Incidence of Postoperative Nausea and Vomiting in Ureteroscopic Procedures Under Spinal Anesthesia
NA · Cairo University · NCT05875077
This study is testing whether using propofol or dexmedetomidine can help reduce nausea and vomiting after surgery for patients at higher risk for these issues.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 45 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | Cairo University (other) |
| Locations | 1 site (Cairo) |
| Trial ID | NCT05875077 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of propofol infusion versus dexmedetomidine infusion in reducing the incidence of postoperative nausea and vomiting (PONV) in patients undergoing ureteroscopic procedures under spinal anesthesia. It focuses on patients aged 18 to 60 years who have multiple risk factors for PONV, such as being female, having a history of PONV, and being non-smokers. The study aims to understand the mechanisms by which these medications may alleviate nausea and vomiting post-surgery, considering the physiological effects of regional anesthesia on the body. By analyzing the outcomes, the study seeks to improve patient recovery experiences and satisfaction.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 18 to 60 years scheduled for ureteroscopic procedures who have more than one risk factor for postoperative nausea and vomiting.
Not a fit: Patients with contraindications for spinal anesthesia or those with a history of allergy to propofol or dexmedetomidine may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly reduce the incidence of postoperative nausea and vomiting, leading to faster recovery and higher patient satisfaction.
How similar studies have performed: Previous studies have explored the effects of propofol and dexmedetomidine on PONV, indicating potential benefits, but this specific comparison in the context of ureteroscopic procedures is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 to 60 years * ASA physical status I-II * Scheduled for ureteroscopic procedure * With more than one Risk factor for PONV (female, history of PONV, non-smoking). Exclusion Criteria: * Patients with contraindications for spinal anesthesia including infection at the injection site, bleeding diathesis, known left ventricular outflow obstruction, hypovolemia, and increased intracranial pressure. * History of allergy or hypersensitivity to propofol or dexmedetomidine. * Gastrointestinal diseases e.g. gastroenteritis and gastric ulcers, ear diseases e.g. infections of middle and inner ear, liver cirrhosis. * Those who have received antiemetic drugs within 48 hours before surgery. * Operations lasting more than two hours. * The patient's unwillingness.
Where this trial is running
Cairo
- Kasralaini Medical School — Cairo, Egypt (RECRUITING)
Study contacts
- Study coordinator: BESHOY ATEF
- Email: beshoyatef01@gmail.com
- Phone: 01220703346
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Nausea and Vomiting, Postoperative